research reports and media, page-3877

Coincidentally PAR's patent attorney was my patent attorney on my early patents and in fact lives two doors down from me on my street. I can assure you he is very aware of the obligations to defend intellectual property and the timelines on which that must happen. I can't imagine him allowing an Arthropharm situation to develop.

Even if you do hold the patents, their defense is incredibly expensive. PAR needs deep pockets or friends with deep pockets if someone decides to infringe. Even so it is a little difficult to see where an infringer would come from. Bene? Seems very unlikely. Some copycat manufacturer?

Patent infringement comes at the point of sale of a copy. In order to infringe, the copycat would have to be in market. Which means that it has had to run its own clinical trials and received FDA approval. This first hurdle is so high that its difficult to see them getting to the point where they even could infringe.